PTK2 and breast carcinoma: In particular, while ERK5 was initially found to be a target of FAK [14], other studies demonstrated that ERK5 promoted breast cancer cell proliferation [15], adhesion-dependent survival [16], and melanoma cell invasiveness [17] through FAK phosphorylation at Ser910.